These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20462263)

  • 21. ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action.
    Fletcher GC; Brokx RD; Denny TA; Hembrough TA; Plum SM; Fogler WE; Sidor CF; Bray MR
    Mol Cancer Ther; 2011 Jan; 10(1):126-37. PubMed ID: 21177375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.
    McLaughlin J; Markovtsov V; Li H; Wong S; Gelman M; Zhu Y; Franci C; Lang D; Pali E; Lasaga J; Low C; Zhao F; Chang B; Gururaja TL; Xu W; Baluom M; Sweeny D; Carroll D; Sran A; Thota S; Parmer M; Romane A; Clemens G; Grossbard E; Qu K; Jenkins Y; Kinoshita T; Taylor V; Holland SJ; Argade A; Singh R; Pine P; Payan DG; Hitoshi Y
    J Cancer Res Clin Oncol; 2010 Jan; 136(1):99-113. PubMed ID: 19609559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.
    Gully CP; Zhang F; Chen J; Yeung JA; Velazquez-Torres G; Wang E; Yeung SC; Lee MH
    Mol Cancer; 2010 Feb; 9():42. PubMed ID: 20175926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.
    Aliagas-Martin I; Burdick D; Corson L; Dotson J; Drummond J; Fields C; Huang OW; Hunsaker T; Kleinheinz T; Krueger E; Liang J; Moffat J; Phillips G; Pulk R; Rawson TE; Ultsch M; Walker L; Wiesmann C; Zhang B; Zhu BY; Cochran AG
    J Med Chem; 2009 May; 52(10):3300-7. PubMed ID: 19402633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aurora kinase inhibitors as anticancer molecules.
    Katayama H; Sen S
    Biochim Biophys Acta; 2010; 1799(10-12):829-39. PubMed ID: 20863917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach.
    Warner SL; Bashyam S; Vankayalapati H; Bearss DJ; Han H; Mahadevan D; Von Hoff DD; Hurley LH
    Mol Cancer Ther; 2006 Jul; 5(7):1764-73. PubMed ID: 16891462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of
    Zhu Y; Ma Y; Zu W; Song J; Wang H; Zhong Y; Li H; Zhang Y; Gao Q; Kong B; Xu J; Jiang F; Wang X; Li S; Liu C; Liu H; Lu T; Chen Y
    J Med Chem; 2020 Jul; 63(13):6748-6773. PubMed ID: 32479083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237.
    Sloane DA; Trikic MZ; Chu ML; Lamers MB; Mason CS; Mueller I; Savory WJ; Williams DH; Eyers PA
    ACS Chem Biol; 2010 Jun; 5(6):563-76. PubMed ID: 20426425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis, SAR and biological evaluation of 1,6-disubstituted-1H-pyrazolo[3,4-d]pyrimidines as dual inhibitors of Aurora kinases and CDK1.
    Le Brazidec JY; Pasis A; Tam B; Boykin C; Black C; Wang D; Claassen G; Chong JH; Chao J; Fan J; Nguyen K; Silvian L; Ling L; Zhang L; Choi M; Teng M; Pathan N; Zhao S; Li T; Taveras A
    Bioorg Med Chem Lett; 2012 Mar; 22(5):2070-4. PubMed ID: 22326168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
    McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological activity of N
    Kurup S; McAllister B; Liskova P; Mistry T; Fanizza A; Stanford D; Slawska J; Keller U; Hoellein A
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):74-84. PubMed ID: 29115879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors.
    Zheng YG; Wang JA; Meng L; Pei X; Zhang L; An L; Li CL; Miao YL
    Eur J Med Chem; 2021 Jan; 209():112934. PubMed ID: 33109396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of a potent and selective aurora kinase inhibitor.
    Oslob JD; Romanowski MJ; Allen DA; Baskaran S; Bui M; Elling RA; Flanagan WM; Fung AD; Hanan EJ; Harris S; Heumann SA; Hoch U; Jacobs JW; Lam J; Lawrence CE; McDowell RS; Nannini MA; Shen W; Silverman JA; Sopko MM; Tangonan BT; Teague J; Yoburn JC; Yu CH; Zhong M; Zimmerman KM; O'Brien T; Lew W
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4880-4. PubMed ID: 18678489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.
    Diamond JR; Eckhardt SG; Tan AC; Newton TP; Selby HM; Brunkow KL; Kachaeva MI; Varella-Garcia M; Pitts TM; Bray MR; Fletcher GC; Tentler JJ
    Clin Cancer Res; 2013 Jan; 19(1):291-303. PubMed ID: 23136197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hit generation and exploration: imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases.
    Bavetsias V; Sun C; Bouloc N; Reynisson J; Workman P; Linardopoulos S; McDonald E
    Bioorg Med Chem Lett; 2007 Dec; 17(23):6567-71. PubMed ID: 17933533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.
    Li J; Hong MJ; Chow JP; Man WY; Mak JP; Ma HT; Poon RY
    Oncotarget; 2015 Apr; 6(11):9327-40. PubMed ID: 25871386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a fluorescence intensity assay for the mitotic serine/threonine protein kinase Aurora-A.
    Slatter AF; Campbell S; Angell RM
    J Biomol Screen; 2013 Feb; 18(2):219-25. PubMed ID: 22983166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.
    Qi W; Cooke LS; Liu X; Rimsza L; Roe DJ; Manziolli A; Persky DO; Miller TP; Mahadevan D
    Biochem Pharmacol; 2011 Apr; 81(7):881-90. PubMed ID: 21291867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benzo[e]pyridoindoles, novel inhibitors of the aurora kinases.
    Hoang TM; Favier B; Valette A; Barette C; Nguyen CH; Lafanechère L; Grierson DS; Dimitrov S; Molla A
    Cell Cycle; 2009 Mar; 8(5):765-72. PubMed ID: 19221479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases.
    Sini P; Gürtler U; Zahn SK; Baumann C; Rudolph D; Baumgartinger R; Strauss E; Haslinger C; Tontsch-Grunt U; Waizenegger IC; Solca F; Bader G; Zoephel A; Treu M; Reiser U; Garin-Chesa P; Boehmelt G; Kraut N; Quant J; Adolf GR
    Mol Cancer Ther; 2016 Oct; 15(10):2388-2398. PubMed ID: 27496137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.